Skip to content

1 Min Read Time


How Microfluidizer Processors Support Vaccine Adjuvant Production

Some of the most commonly used adjuvants are oil in water nano-emulsions. These adjuvants are ideal for pandemic vaccines because their antibody response and safety is well understood.
MF59, which has been approved for the flu vaccine, has been developed for pandemic vaccines by the
Infectious Disease Research Institute and others. These adjuvants can be produced quickly, and can greatly increase the efficacy of the vaccine while limiting the quantity of antigen that is required per dose. The high shear rates and uniform processing generated by Microfluidizer® technology enables sterile filtration of emulsions at production scales.

Many other types of recombinant molecules are processed with Microfluidizer® technology. Any recombinant process that requires cell disruption will benefit from consistent processing which will enable cell disruption at the lowest energy levels possible. Low input energy and efficient cooling ensures that the molecules that are being produced have the highest chance of maintaining activity.

Our line of cGMP processors ensures that the products are made in an environment that will allow for very quick vaccine adjuvant production from the time of order.

For future reading please visit

  1. Production of Nanoemulsion Adjuvants Using High Shear Fluid Processing
  2. Cell disruption for production of recombinant proteins
  3. Microfluidics Vaccine Development and Technology Resources Page
Download the Microfluidics Brochure
Posted by Matt Baumber
Find me on:


Blog articles direct to your inbox




Subscribe to the Microfluidics blog

For the latest news, insight and updates.


Since 2011, Microfluidics has been a member of the IDEX Corporation family of companies. IDEX is a global leader in highly engineered systems and components.

About us